Go or no go? Roche’s fresh start for a new year
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
Go or go go? J&J’s cell therapy heads to the FDA
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
Coronavirus saves the day for Pfizer
But a lacklustre pipeline could stoke the need for deals.
Combining forces in metabolic disorders
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
Hope replaces hype for coronavirus stocks
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Ascendis shoots higher on pivotal win
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.